Kere J The molecular genetics and neurobiology of developmental dyslexia as model of a complex phenotype. Biochem Biophys Res Commun. 2014 Sep 19;452(2):236-43. doi: 10.1016/j.bbrc.2014.07.102. Epub 2014 Jul 28. Review.
Kujala T, Lovio R, Lepistö T, Laasonen M, Näätänen R Evaluation of multi-attribute auditory discrimination in dyslexia with the mismatch negativity. Clin Neurophysiol. 2006 Apr;117(4):885-93. Epub 2006 Feb 23.
Kujala T, Näätänen R The mismatch negativity in evaluating central auditory dysfunction in dyslexia. Neurosci Biobehav Rev. 2001 Aug;25(6):535-43. Review.
Kujala T, Tervaniemi M, Schröger E The mismatch negativity in cognitive and clinical neuroscience: theoretical and methodological considerations. Biol Psychol. 2007 Jan;74(1):1-19. Epub 2006 Jul 17. Review.
Lankinen K, Saari J, Hari R, Koskinen M Intersubject consistency of cortical MEG signals during movie viewing. Neuroimage. 2014 May 15;92:217-24. doi: 10.1016/j.neuroimage.2014.02.004. Epub 2014 Feb 12.
Lovio R, Halttunen A, Lyytinen H, Näätänen R, Kujala T Reading skill and neural processing accuracy improvement after a 3-hour intervention in preschoolers with difficulties in reading-related skills. Brain Res. 2012 Apr 11;1448:42-55. doi: 10.1016/j.brainres.2012.01.071. Epub 2012 Feb 7.
Lovio R, Näätänen R, Kujala T Abnormal pattern of cortical speech feature discrimination in 6-year-old children at risk for dyslexia. Brain Res. 2010 Jun 4;1335:53-62. doi: 10.1016/j.brainres.2010.03.097. Epub 2010 Apr 8.
Lyon, G R. et al., 2003. Defining Dyslexia , Comorbidity , Teachers ' Knowledge of Language and Reading A Definition of Dyslexia. Annals of Dyslexia, 53(1), pp.1-14.
Mittag M, Thesleff P, Laasonen M, Kujala T The neurophysiological basis of the integration of written and heard syllables in dyslexic adults. Clin Neurophysiol. 2013 Feb;124(2):315-26. doi: 10.1016/j.clinph.2012.08.003. Epub 2012 Aug 30.
Näätänen R, Paavilainen P, Rinne T, Alho K The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol. 2007 Dec;118(12):2544-90. Epub 2007 Oct 10. Review.
Nevala, J , Kairaluoma, L. & Ahonen, T., 2006. Lukemis-ja kirjoittamistaitojen yksilötestistö nuorille ja aikuisille. Jyväskylä: Niilo Mäki
Ramus F, Marshall CR, Rosen S, van der Lely HK Phonological deficits in specific language impairment and developmental dyslexia: towards a multidimensional model. Brain. 2013 Feb;136(Pt 2):630-45. doi: 10.1093/brain/aws356.
Ramus F Dyslexia. Talk of two theories. Nature. 2001 Jul 26;412(6845):393-5.
Salmelin R Clinical neurophysiology of language: the MEG approach. Clin Neurophysiol. 2007 Feb;118(2):237-54. Epub 2006 Sep 27. Review.
Scerri TS, Schulte-Körne G Genetics of developmental dyslexia. Eur Child Adolesc Psychiatry. 2010 Mar;19(3):179-97. doi: 10.1007/s00787-009-0081-0. Epub 2009 Nov 29. Review.
Shtyrov Y, Nikulin VV, Pulvermüller F Rapid cortical plasticity underlying novel word learning. J Neurosci. 2010 Dec 15;30(50):16864-7. doi: 10.1523/JNEUROSCI.1376-10.2010.
Temple E Brain mechanisms in normal and dyslexic readers. Curr Opin Neurobiol. 2002 Apr;12(2):178-83. Review.
Wechsler, D , 1997. The Wechsler Memory Scale (Third Edition), San Antonio, TX: The Psychological Corporation. Helsinki: Psykologien kustannus Oy.
Wechsler, D , 1997. Wechsler Adult Intelligence Scale (Third Edition), San Antonio, TX: The Psychological Corporation. Helsinki: Psykologien kustannus Oy.
Wolf M Rapid alternating stimulus naming in the developmental dyslexias. Brain Lang. 1986 Mar;27(2):360-79. Review.
Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
